It was a tough start to the week for US biotech giant Gilead (Nasdaq: GILD), with the company’s share price taking a battering in the stock market slump and after reproting financing results that revealed fading hepatitis sales.
But better news on Wednesday that hinted at a new source of sales in another therapy area, sent Gilead’s share price spiraling, and it closed at $82.76, a 3% rise on the previous close.
The news was that the US Food and Drug Administration (FDA) has approved Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a once-daily single-tablet regimen (STR) for the treatment of HIV-1 infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze